Found 165 Cancer trials
A listing of Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
S
Sandeep Batra, MD
This randomized phase III clinical trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
B
Bryan Schneider, MD
Phase 3
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy andy of giredestrant plus everolimus compared with the physician's choice of endocrineherapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with …
ARE YOU A BREAST CANCER SURVIVOR? Join Our Study and Help Researchers Learn More About Treating Cognitive Problems Attributed to Chemotherapy
B
Brenna McDonald
ARE YOU A BREAST CANCER SURVIVOR? HAVE YOU NOTICED ANY PROBLEMS WITH YOUR COGNITIVE FUNCTION - MEMORY, ATTENTION, ABILITY TO MULTI-TASK - AFTER COMPLETING CHEMOTHERAPY? Researchers at Indiana University School of Medicine and the University of Pittsburgh are seeking volunteers to take part in a study looking at two …
A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver
M
Mark Tann, MD
The primary question of interest is quantifying the relationship between Y-90 liver therapy and liver damage.
A Pilot Study to assess Theragnostically Planned Liver Radiation with Functional DVH Analysis to Optimize Individualized Radiation Therapy
R
Ryan Rhome, MD
The purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer.
A Phase III International Randomized Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
S
S. Hamid Sayer, MD
The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R …
The Indiana Myeloma Registry
R
Rafat Abonour, MD
WHAT IS CANCER?WHAT IS MULTIPLE MYELOMA?WHAT IS THE STUDY ABOUT?What is cancer?Each cell in your body holds a copy of your DNA. This DNA tells your cells how to do their jobs, like when to copy themselves and when to delete. Your cells copy and delete all the time. This …
Study of Oral MRT-2359 in Selected Cancer Patients
M
Mateusz Opyrchal, MD, PhD
Phase 1/2
This Phase 1/2, open-label, multicenter study is conducted in patients with previouslyd selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung(SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cellymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular …
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
S
Sherif Farag, MD
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and otherdications.
A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
J
Jodi Skiles
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT).
